Approval · Notice of Compliance 5545 · 2004
ZOMETA: Notice of Compliance 5545
Issued October 6, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 5545
- Date
- October 6, 2004
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Extension data to support long term use in the treatment of bone metastases of solid tumours and osteolytic lesions of multiple myeloma
- Therapeutic class
- Bone metabolism regulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZOMETA | Not yet assigned | — |
Medicinal ingredients
- ZOLEDRONIC ACID 4 MG per VIAL
- ZOLEDRONIC ACID 4 MG per 5ML